Logo

BLCO

Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation • NYSE
$16.19 ▼ -0.06% (-0.01)
Market Cap $5.73 B
52w High $20.71
52w Low $10.45
Dividend Yield 0%
P/E -18.83
Volume 119.49K
Outstanding Shares 354.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.281B ▲ $676M ▼ $-28M ▲ -2.186% ▲ $-0.08 ▲ $207M ▲
Q2-2025 $1.278B ▲ $764M ▲ $-62M ▲ -4.851% ▲ $-0.18 ▲ $88M ▲
Q1-2025 $1.137B ▼ $738M ▲ $-212M ▼ -18.646% ▼ $-0.6 ▼ $20M ▼
Q4-2024 $1.28B ▲ $692M ▲ $-3M ▼ -0.234% ▼ $-0.009 ▼ $194M ▲
Q3-2024 $1.196B $689M $4M 0.334% $0.011 $152M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $310M ▲ $13.832B $7.332B ▲ $6.429B ▼
Q2-2025 $272M ▲ $13.832B ▲ $7.324B ▲ $6.44B ▲
Q1-2025 $202M ▼ $13.428B ▼ $6.995B ▲ $6.361B ▼
Q4-2024 $305M ▼ $13.469B ▼ $6.925B ▲ $6.473B ▼
Q3-2024 $329M $13.515B $6.854B $6.589B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-28M ▲ $139.054M ▲ $-61.302M ▲ $-12.55M ▼ $60M ▲ $64.533M ▲
Q2-2025 $-58M ▲ $35M ▲ $-90M ▲ $90M ▲ $57M ▲ $-54M ▲
Q1-2025 $-211M ▼ $-25M ▼ $-116M ▲ $31M ▼ $-101M ▼ $-135M ▼
Q4-2024 $-2M ▼ $22M ▼ $-185M ▼ $146M ▲ $-34M ▼ $-70M ▼
Q3-2024 $8M $154M $-96M $-20M $48M $94M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Branded and Other Generic Products
Branded and Other Generic Products
 $70.00M ▲$50.00M ▼$60.00M ▲$60.00M ▲
Device Products
Device Products
 $480.00M ▲$450.00M ▼$470.00M ▲$480.00M ▲
Other Revenues
Other Revenues
 $10.00M ▲$0 ▼$10.00M ▲$0 ▼
Over the Counter Products
Over the Counter Products
 $460.00M ▲$410.00M ▼$480.00M ▲$450.00M ▼
Pharmaceutical Products
Pharmaceutical Products
 $270.00M ▲$220.00M ▼$260.00M ▲$280.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Bausch + Lomb has been growing its sales at a healthy pace, with revenue rising steadily over the past several years. The core business clearly has demand, and gross profits have kept up, which suggests the underlying product portfolio is still attractive. However, profitability remains thin. Operating income is positive but modest relative to sales, and net income has slipped into losses in recent years after only a brief period of small profits. This points to pressure from costs, interest expense, and possibly pricing. In short, the company is successfully selling more, but has not yet translated that into consistently solid bottom‑line results.

Balance Sheet

Balance Sheet The company operates with a sizable asset base, reflecting its global footprint, manufacturing, and product portfolio. That said, the balance sheet has become more leveraged over time. Debt has climbed sharply compared with earlier years, while shareholders’ equity has gradually drifted down. Cash balances remain relatively small for a business of this scale, which limits the immediate cushion against shocks. Overall, the capital structure looks more stretched than a few years ago, and the company appears more dependent on maintaining access to credit markets and improving earnings to keep leverage manageable.

Cash Flow

Cash Flow Cash generation has been uneven. Bausch + Lomb used to produce solid operating cash flow, but more recently this has weakened and turned choppy, only modestly positive in the latest year. After funding ongoing investments in plants, equipment, and product capabilities, free cash flow has swung from clearly positive to slightly negative. This pattern suggests the business can generate cash but is not yet doing so consistently or in large amounts relative to its needs. It leaves less room for rapid debt reduction, large acquisitions, or aggressive shareholder returns without either stronger earnings or additional financing.

Competitive Edge

Competitive Edge Bausch + Lomb holds a long‑established, globally recognized brand in eye health, which is a significant advantage in a trust‑driven category. Its portfolio spans contact lenses, lens care solutions, surgical devices, and eye pharmaceuticals, giving it a diversified presence across most major eye‑care segments. Industry research characterizes this as a “narrow moat”: the company has defensible strengths in brand, distribution relationships, and patented products, but faces intense competition from other large eye‑care players and from lower‑priced generic drugs. Product recalls and pricing pressure are ongoing risks that could chip away at this position if not carefully managed.

Innovation and R&D

Innovation and R&D Innovation is a clear strategic focus and a major part of Bausch + Lomb’s story. The company has a long history of firsts in contact lenses and continues to invest in advanced materials, comfort technologies, and optics, such as its MoistureSeal and ProBalance platforms. These are designed to address everyday problems like dryness and digital eye strain, which can strengthen customer loyalty. Looking ahead, the pipeline is broad: myopia‑control solutions for children, “bioactive” lens materials that embed hydration directly into the lens, new surgical systems and premium intraocular lenses, and novel dry‑eye treatments. If successfully developed and commercialized, these could shift the mix toward higher‑growth, higher‑margin products. Execution risk is meaningful, though, as regulatory approvals, clinical data, and market adoption all need to align.

Summary

Bausch + Lomb is growing its top line steadily in an attractive, long‑term eye‑health market and maintains a respected global brand with a diversified product set. However, profitability is still relatively weak, with recent years marked by net losses despite rising sales, pointing to cost, pricing, and interest‑expense challenges. The balance sheet now carries considerably more debt than in the past and only modest cash, which raises the importance of improving margins and stabilizing cash flow. Cash generation has become less reliable, leaving less financial flexibility than a business of this scale might ideally have. On the positive side, the company’s innovation engine appears active and well aligned with major industry trends, including myopia control, premium contact lenses, advanced surgical systems, and dry‑eye therapies. The key questions going forward are whether Bausch + Lomb can convert this pipeline and its brand strength into sustainably higher margins and more consistent free cash flow, while managing competitive pressures and its higher leverage.

NEWS

November 18, 2025 · 4:30 PM UTC

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Read more

November 10, 2025 · 6:59 AM UTC

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Read more

October 29, 2025 · 6:58 AM UTC

Bausch + Lomb Announces Third-Quarter 2025 Results

Read more

September 29, 2025 · 7:15 AM UTC

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Read more